Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Horm Metab Res ; 2024 Apr 02.
Artigo em Inglês | MEDLINE | ID: mdl-38565183

RESUMO

The aim was to compare the lipid profile of patients with GD treated with anti-thyroid drugs (ATDs) using a titration regimen versus a block and replace regimen. This is an 18-month prospective observational study. In this study were included 149 medically treated GD patients, aged+>+18 years. Pregnant women and patients treated with radioactive iodine therapy or partial/total thyroidectomy were excluded. Patients were divided into 2 subgroups: titration (A) and block and replace (B) therapy, according to the ATD regimen used. Thyroid and metabolic profile was measured at baseline and at least one visit during medical treatment. The whole group included 122 (81.87%) females (F) and 27 (18.12%) males (M), ratio F:M=4.5:1. As expected, at the time of diagnosis, thyrotoxic patients were with normal lipid profile. During medical treatment, in patients who achieved euthyroidism, the cholesterol levels increased as follows: in subgroup A: by 52.9 mg/dl (95% CI: 26.4-79.3), p<0.001 for total cholesterol (T-C), by 33.3 mg/dl (95% CI: 10.3-56.3), p=0.007 for low-density lipoprotein cholesterol (LDL-C) and by 11.44 mg/dl (95% CI: 3.08-19.79), p=0.009 for high-density lipoprotein cholesterol (HDL-C); in subgroup B T-C increased by 45.1 mg/dl (95% CI: 22.2-68), p<0.001 and for LDL-C by 33.57 mg/dl (95% CI: 12.72-54.42), p=0.003. No statistically significant increase in triglyceride levels was determined. Medical treatment of hyperthyroidism due to Graves' disease increased cholesterol levels regardless of the ATD regimen used.

2.
Hormones (Athens) ; 15(2): 224-234, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-27376425

RESUMO

BACKGROUND: Somatostatin analogs (SSA) are now considered standard therapy for acromegaly, as primary or adjunctive treatment after pituitary surgery. OBJECTIVE: To evaluate the efficacy of SSA and the effect of dose escalation in non-operated patients with acromegaly as compared to patients treated after pituitary surgery in a Romanian tertiary care center. DESIGN: Retrospective study of 73 consecutively evaluated patients with acromegaly treated with SSA, divided into 2 groups: 11 patients (4M/7F, 21-62 years) with primary treatment and 62 patients (22M/40F, 21-68 years) treated after surgery. They received Octreotide LAR 20-30 mg i.m./28 days or Lanreotide SR 30 mg i.m./14/10/7 days. Random serum growth hormone (GH) was measured using IRMA, sensitivity 0.2-0.01 µg/L IGF-1 was measured using different assays and compared with ULN for age and sex. RESULTS: Overall, random GH ≤2.5 µg/L was attained in 39 patients (53.4%) and optimal GH ≤1 ng/mL) in 30 patients (41%), while normal IGF-1 was recorded in 22/72 patients (30.5%). The final random GH ≤2.5 µg/L was achieved in 27.2% of non-operated patients (3/11) as compared with 58% (36/62) of patients treated medically after pituitary surgery, p<0.05. Escalation of doses of SSA applied in 43 patients improved the number of controlled patients by 5 (12.1%, p=0.059) and the number of optimally controlled patients by 9.7%. Of the 8 patients who switched from Lanreotide to Octreotide, 2 patients achieved GH normalization. CONCLUSION: The rate of biochemical control via SSA treatment in patients with acromegaly could be improved by rise of the SSA dose or by debulking surgery. Occasionally, substituting one SSA for another may be of benefit.


Assuntos
Acromegalia/terapia , Adenoma/terapia , Antineoplásicos/administração & dosagem , Procedimentos Cirúrgicos de Citorredução , Adenoma Hipofisário Secretor de Hormônio do Crescimento/terapia , Peptídeos Cíclicos/administração & dosagem , Somatostatina/análogos & derivados , Acromegalia/sangue , Acromegalia/diagnóstico , Acromegalia/etiologia , Adenoma/sangue , Adenoma/complicações , Adenoma/diagnóstico , Adulto , Idoso , Antineoplásicos/efeitos adversos , Biomarcadores Tumorais/sangue , Quimioterapia Adjuvante , Procedimentos Cirúrgicos de Citorredução/efeitos adversos , Feminino , Adenoma Hipofisário Secretor de Hormônio do Crescimento/sangue , Adenoma Hipofisário Secretor de Hormônio do Crescimento/complicações , Adenoma Hipofisário Secretor de Hormônio do Crescimento/diagnóstico , Hormônio do Crescimento Humano/sangue , Humanos , Fator de Crescimento Insulin-Like I/metabolismo , Masculino , Pessoa de Meia-Idade , Terapia Neoadjuvante , Peptídeos Cíclicos/efeitos adversos , Estudos Retrospectivos , Romênia , Somatostatina/administração & dosagem , Somatostatina/efeitos adversos , Centros de Atenção Terciária , Fatores de Tempo , Resultado do Tratamento , Adulto Jovem
3.
Pituitary ; 16(2): 168-74, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-22562529

RESUMO

In normal subjects growth hormone (GH) and insulin-like growth factor-I (IGF-I) have opposing effects on glucose metabolism. Active acromegaly is associated with insulin resistance (IR) and glucose intolerance although both GH and IGF-I are elevated. Our objective was to compare whether GH or IGF-I correlates more closely with IR and glucose intolerance in acromegaly. Basal serum IGF-I and GH, glucose and insulin during an oral glucose tolerance test were measured in 70 normoglycemic and 44 hyperglycemic acromegalic patients (21 impaired fasting glucose, 11 impaired glucose tolerance and 12 diabetes mellitus) according to American Diabetes Association criteria. 55 patients were assessed before any treatment for acromegaly and 59 after surgery and/or radiotherapy (15 patients had normal IGF-I after treatment). Patients treated with somatostatin analogs, GH-receptor antagonists or antidiabetic drugs were excluded. IR was assessed by various basal and stimulated indices. Homeostatic Model Assessment 2-Insulin Resistance (HOMA2-IR) index correlated more closely with IGF-I (r = 0.65, p < 0.0001) than nadir (r = 0.23, p = 0.008) or random GH (r = 0.26, p = 0.002). HOMA2-IR correlated better with IGF-I than nadir or random GH also in normoglycemic (n = 70; r = 0.74, p < 0.0001 vs. r = 0.36, p = 0.001 vs. r = 0.39, p < 0.001) and hyperglycemic patients (n = 44; r = 0.54, p = 0.0002 vs. r = 0.09, p = 0.4 vs. r = 0.14, p = 0.26). In multivariate logistic regression analysis IGF-I but not GH was a significant risk factor for glucose intolerance after adjusting for age, sex, weight and acromegaly duration (OR = 1.56, p = 0.01). In acromegaly IGF-I correlates more closely than GH with IR. IGF-I levels but not GH are associated with glucose intolerance.


Assuntos
Acromegalia/sangue , Intolerância à Glucose/fisiopatologia , Hormônio do Crescimento Humano/sangue , Resistência à Insulina/fisiologia , Fator de Crescimento Insulin-Like I/metabolismo , Acromegalia/metabolismo , Adulto , Feminino , Intolerância à Glucose/sangue , Humanos , Masculino , Pessoa de Meia-Idade , Fatores de Risco
4.
Rom J Intern Med ; 44(1): 49-59, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-17236287

RESUMO

UNLABELLED: The measurement of salivary cortisol provides a stress-free, non-invasive collection procedure, which reflects the changes in the hormone plasma levels. The aims of the present study were to determine the level of stress displayed by healthy patients who underwent different types of routine dental treatment procedures and to detect a possible correlation between cortisol and oxidative stress in periodontal disease. MATERIAL AND METHODS: 36 subjects took part in this study. Patients received routine dental procedures or underwent oral surgery. The physiologic stress response was determined using salivary cortisol assessment. Total antioxidant capacity of saliva and uric acid was also measured. Salivary cortisol assessment was made in whole saliva by an ELISA extraction-free technique using a Serozyme Cortisol kit (ADALTIS, Italy) for serum and urine and adapted to saliva. Method's sensibility for saliva is 0.55 ng/mL. Uric acid was measured by uricase using a kit from Diamedix and the total antioxidant capacity (TAC) using the spectrophotometric assay, also called "Trolox equivalent antioxidant capacity" (TEAC). This method is an adaptation of the ABTS assay. RESULTS: Cortisol levels are influenced by the duration and types of treatment and anesthesia. The results indicate that saliva of healthy individuals is significantly more effective than that of patients with periodontal diseases in scavenging a wide variety of generated free radicals. CONCLUSIONS: Within the limits of this study, there is a relationship between salivary cortisol levels, time and intensity of various dental treatment procedures. Periodontal diseases are associated with oxidative stress and a defect in the total antioxidant activity of saliva.


Assuntos
Ansiedade ao Tratamento Odontológico , Assistência Odontológica , Hidrocortisona/análise , Saliva/metabolismo , Estresse Fisiológico/metabolismo , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Biomarcadores , Humanos , Pessoa de Meia-Idade , Estresse Fisiológico/etiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...